

Accepted Manuscript

Hot Topic

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

Robert L. Ferris, Heinz-Josef Lenz, Anna Maria Trotta, Jesús García-Foncillas, Jeltje Schulten, François Audhuy, Marco Merlano, Gerard Milano

PII: S0305-7372(17)30200-1
DOI: <https://doi.org/10.1016/j.ctrv.2017.11.008>
Reference: YCTRV 1705

To appear in: *Cancer Treatment Reviews Cancer Treatment Reviews*

Received Date: 21 August 2017
Revised Date: 17 November 2017
Accepted Date: 18 November 2017

Please cite this article as: Ferris, R.L., Lenz, H-J., Maria Trotta, A., García-Foncillas, J., Schulten, J., Audhuy, F., Merlano, M., Milano, G., Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation, *Cancer Treatment Reviews Cancer Treatment Reviews* (2017), doi: <https://doi.org/10.1016/j.ctrv.2017.11.008>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title: Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

Robert L. Ferris^a, Heinz-Josef Lenz^b, Anna Maria Trotta^c, Jesús García-Foncillas^d, Jeltje Schulten^e, François Audhuy^f, Marco Merlano^g, Gerard Milano^h

^a Department of Otolaryngology, University of Pittsburgh Cancer Institute, University of Pittsburgh, 5117 Centre Avenue, Suite 2.26; Pittsburgh, PA, 15213, United States; ^b Division of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA, United States; ^c Immunology Unit Functional Genomics, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale," Naples, Italy; ^d Cancer Institute, "Fundación Jiménez Díaz" University Hospital, Autonomous University, Madrid, Spain; ^e Merck KGaA, Darmstadt, Germany; ^f Merck Santé SAS and Merck Serono SAS; 37 rue Saint-Romain 69008, Lyon, France; ^g Department of Medicine, Head Clinical Oncology and Translational Research S. Croce and Carle University Teaching Hospital and ARCO Foundation, via M. Coppino 26, 12100 Cuneo, Italy, mcmerlano@gmail.com; ^h Oncopharmacology Unit, Centre Antoine Lacassagne, 33 avenue Valombrose, 06189 Nice, Cedex 2, France.

Corresponding Authors' Contact Information:

Dr Gerard Milano
Centre Antoine Lacassagne
33 avenue Valombrose
06189 Nice Cedex 2 France
Phone: (+33) 4 92 03 15 53
Email: gerard.milano@nice.unicancer.fr

Dr. Robert L. Ferris
UPMC Hillman Cancer Center
5117 Centre Avenue
Suite 2.26
Pittsburgh, PA 15213
Phone: 412-623-3959
Email: ferrrl@UPMC.EDU

Download English Version:

<https://daneshyari.com/en/article/8785898>

Download Persian Version:

<https://daneshyari.com/article/8785898>

[Daneshyari.com](https://daneshyari.com)